AZD7325 + AZD7325 + AZD7325 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anxiety Disorders
Conditions
Anxiety Disorders
Trial Timeline
Dec 1, 2008 → May 1, 2009
NCT ID
NCT00808249About AZD7325 + AZD7325 + AZD7325 + Placebo
AZD7325 + AZD7325 + AZD7325 + Placebo is a phase 2 stage product being developed by AstraZeneca for Anxiety Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00808249. Target conditions include Anxiety Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00808249 | Phase 2 | Completed |
Competing Products
20 competing products in Anxiety Disorders